You keep harping on the low numbers in the 2a, but it clearly shows increased efficacy at 200 versus 50 or 100. I would buy your argument more if the other 2 lower doses showed similar signs. At least we'll all know very soon. In the past when management has put out PR's and blogs reminding us of a trial, it was telling of positive data to be announced. Why would it be different this time?
News 
Market Data 
Discover 
